This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
Therapeutic Area (MeSH)
ATC Code
C01EB18
ATC Item
ranolazine
Pharmacotherapeutic Group
Cardiac therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ranolazine | N/A | 多司马酯 |
EMA Name
Ranexa (previously Latixa)
Medicine Name
Ranexa (previously Latixa)
Aliases
N/ANo risk management plan link.
